Penn Medicine’s iStar emerges as a game-changing AI tool, developed by Perelman School of Medicine experts. This revolutionary application, short for Inferring Super-Resolution Tissue Architecture, presents a paradigm shift in oncology diagnostics. iStar delves…
Continue Reading
GE HealthCare’s AI can accurately predict patient responses to immunotherapy, as demonstrated in collaborative studies with VUMC and UME. The models, showcasing 70-80% accuracy, may guide more personalized treatment decisions, potentially minimizing side effects…
Continue Reading
Lunit SCOPE IO, driven by AI, achieved a groundbreaking success in a phase III trial for NSCLC patients with EGFR or ALK mutations, published in the Journal of Clinical Oncology. This marks a pivotal…
Continue Reading
In the relentless global battle against cancer, generative artificial intelligence (Gen AI) has emerged as a powerful tool in oncology’s arsenal. With the capacity to analyse vast datasets, simulate complex molecular interactions, and tailor…
Continue Reading
Dr. Jose E Vidal who is currently the CEO of CytoImmune Therapeutics, a company at the forefront of a novel natural killer cell therapy for lung cancer, currently in phase 1 clinical trials joins…
Continue Reading
Researchers at the Mount Sinai Hospital have developed an mRNA-based treatment for cancer. The approach combines the delivery of mRNA therapy in lipid nanoparticles and also involves co-delivering dendritic cells that have also been…
Continue Reading
